Market Closed -
Nasdaq
04:00:00 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
52.94
USD
|
-0.66%
|
|
-11.75%
|
+92.51%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
406.5
|
509.9
|
1,357
|
716.3
|
1,588
|
3,507
|
-
|
-
|
Enterprise Value (EV)
1 |
166.7
|
509.9
|
1,357
|
716.3
|
1,588
|
3,507
|
3,507
|
3,507
|
P/E ratio
|
-6.18
x
|
-6
x
|
-18.4
x
|
-5.3
x
|
-9.17
x
|
-17.9
x
|
-15.4
x
|
-16.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.1
x
|
17
x
|
27.6
x
|
17.2
x
|
36.1
x
|
85.6
x
|
65.5
x
|
32.6
x
|
EV / Revenue
|
13.1
x
|
17
x
|
27.6
x
|
17.2
x
|
36.1
x
|
85.6
x
|
65.5
x
|
32.6
x
|
EV / EBITDA
|
-7.07
x
|
-
|
-15.3
x
|
-4.5
x
|
-10.3
x
|
-18
x
|
-18.7
x
|
-21.5
x
|
EV / FCF
|
-6.23
x
|
-6.28
x
|
-22.4
x
|
-4.55
x
|
-10.9
x
|
-20.5
x
|
-18.7
x
|
-22.8
x
|
FCF Yield
|
-16.1%
|
-15.9%
|
-4.46%
|
-22%
|
-9.21%
|
-4.87%
|
-5.35%
|
-4.39%
|
Price to Book
|
3.1
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,870
|
29,089
|
42,672
|
46,303
|
57,733
|
66,238
|
-
|
-
|
Reference price
2 |
14.08
|
17.53
|
31.80
|
15.47
|
27.50
|
52.94
|
52.94
|
52.94
|
Announcement Date
|
3/12/20
|
3/16/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
31.13
|
29.94
|
49.11
|
41.59
|
43.95
|
40.97
|
53.57
|
107.5
|
EBITDA
1 |
-57.52
|
-
|
-88.73
|
-159.1
|
-154.2
|
-195.1
|
-187.9
|
-163.1
|
EBIT
1 |
-58.66
|
-75.88
|
-89.98
|
-160
|
-156.5
|
-193.6
|
-222.6
|
-235.1
|
Operating Margin
|
-188.41%
|
-253.41%
|
-183.22%
|
-384.84%
|
-356.22%
|
-472.63%
|
-415.51%
|
-218.68%
|
Earnings before Tax (EBT)
1 |
-54.96
|
-85.01
|
-66.58
|
-130.2
|
-151.7
|
-167.3
|
-212.9
|
-220.5
|
Net income
1 |
-55.15
|
-85.51
|
-66.82
|
-131.2
|
-154.9
|
-176.9
|
-224.9
|
-215.7
|
Net margin
|
-177.15%
|
-285.59%
|
-136.06%
|
-315.48%
|
-352.56%
|
-431.86%
|
-419.89%
|
-200.6%
|
EPS
2 |
-2.280
|
-2.920
|
-1.730
|
-2.920
|
-3.000
|
-2.965
|
-3.439
|
-3.143
|
Free Cash Flow
1 |
-65.27
|
-81.19
|
-60.5
|
-157.5
|
-146.2
|
-170.9
|
-187.7
|
-154.1
|
FCF margin
|
-209.65%
|
-271.14%
|
-123.19%
|
-378.7%
|
-332.65%
|
-417.14%
|
-350.39%
|
-143.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/16/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
14.71
|
11.66
|
12.68
|
6.581
|
10.67
|
13.5
|
10.48
|
11.03
|
8.939
|
7.889
|
8.428
|
8.721
|
15.99
|
5.258
|
4.169
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-46.97
|
-
|
-46.65
|
-47.59
|
-48.22
|
-
|
-
|
EBIT
1 |
-22.86
|
-27.07
|
-31.11
|
-48.2
|
-53.66
|
-36.75
|
-33.88
|
-38.37
|
-47.54
|
-46.81
|
-48.73
|
-51.08
|
-45.91
|
-59.33
|
-62.43
|
Operating Margin
|
-155.45%
|
-232.29%
|
-245.25%
|
-732.34%
|
-503.12%
|
-272.26%
|
-323.45%
|
-347.76%
|
-531.85%
|
-593.35%
|
-578.18%
|
-585.67%
|
-287.05%
|
-1,128.39%
|
-1,497.47%
|
Earnings before Tax (EBT)
1 |
-14.28
|
-18.78
|
-5.583
|
-24.29
|
-81.58
|
-40.2
|
-30.54
|
-21.89
|
-59.12
|
-33.36
|
-44.6
|
-46.45
|
-40.81
|
-52.35
|
-56.25
|
Net income
1 |
-14.42
|
-18.89
|
-5.714
|
-24.62
|
-81.97
|
-39.74
|
-32.03
|
-23.01
|
-60.15
|
-34.46
|
-45.66
|
-48.97
|
-46.93
|
-57.23
|
-60.5
|
Net margin
|
-98.04%
|
-162.1%
|
-45.05%
|
-374.03%
|
-768.54%
|
-294.4%
|
-305.78%
|
-208.57%
|
-672.93%
|
-436.76%
|
-541.71%
|
-561.52%
|
-293.46%
|
-1,088.45%
|
-1,451.1%
|
EPS
2 |
-0.3400
|
-0.4300
|
-0.1300
|
-0.5300
|
-1.810
|
-0.8600
|
-0.6600
|
-0.4300
|
-1.090
|
-0.5900
|
-0.7718
|
-0.8118
|
-0.7618
|
-0.9050
|
-0.9250
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/3/22
|
2/28/23
|
5/4/23
|
8/7/23
|
11/2/23
|
2/28/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
240
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-65.3
|
-81.2
|
-60.5
|
-157
|
-146
|
-171
|
-188
|
-154
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-31.9%
|
-46.6%
|
-51.4%
|
-49.9%
|
-28.4%
|
-31.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.550
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.600
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.22
|
1.29
|
0.87
|
7.59
|
3.98
|
4.77
|
5.3
|
5.67
|
Capex / Sales
|
7.14%
|
4.3%
|
1.77%
|
18.24%
|
9.06%
|
11.64%
|
9.89%
|
5.27%
|
Announcement Date
|
3/12/20
|
3/16/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
52.94
USD Average target price
80.18
USD Spread / Average Target +51.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +92.51% | 3.51B | | +15.55% | 121B | | +12.66% | 107B | | -2.53% | 24.82B | | +1.11% | 22.48B | | -9.72% | 18.32B | | -42.28% | 16.33B | | -18.92% | 15.31B | | +6.19% | 14.08B | | +28.83% | 11.74B |
Bio Therapeutic Drugs
|